Insider Selling: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Insider Sells 3,635 Shares of Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) insider Dallan Murray sold 3,635 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the completion of the transaction, the insider now directly owns 18,125 shares in the company, valued at approximately $2,537,500. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Sarepta Therapeutics Stock Down 2.5 %

SRPT stock opened at $132.58 on Thursday. The firm’s fifty day simple moving average is $125.37 and its 200-day simple moving average is $111.22. The company has a market capitalization of $12.53 billion, a P/E ratio of 1,205.27 and a beta of 0.95. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The business had revenue of $413.50 million for the quarter, compared to the consensus estimate of $375.52 million. During the same period in the prior year, the firm earned ($1.44) EPS. The business’s revenue for the quarter was up 63.1% on a year-over-year basis. As a group, equities research analysts forecast that Sarepta Therapeutics, Inc. will post 2.23 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on SRPT shares. TheStreet raised shares of Sarepta Therapeutics from a “d” rating to a “c-” rating in a research report on Monday, March 4th. Royal Bank of Canada lifted their price objective on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a research report on Thursday, February 29th. Cantor Fitzgerald reissued a “neutral” rating and set a $128.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, May 2nd. JPMorgan Chase & Co. dropped their target price on shares of Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating on the stock in a research report on Friday, May 3rd. Finally, UBS Group boosted their target price on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $160.60.

Hedge Funds Weigh In On Sarepta Therapeutics

Several large investors have recently made changes to their positions in the company. ProShare Advisors LLC lifted its stake in shares of Sarepta Therapeutics by 10.1% in the 1st quarter. ProShare Advisors LLC now owns 6,578 shares of the biotechnology company’s stock valued at $852,000 after purchasing an additional 601 shares during the period. US Bancorp DE lifted its stake in shares of Sarepta Therapeutics by 11.6% in the 1st quarter. US Bancorp DE now owns 8,415 shares of the biotechnology company’s stock valued at $1,089,000 after purchasing an additional 876 shares during the period. Sei Investments Co. lifted its stake in shares of Sarepta Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 61,451 shares of the biotechnology company’s stock valued at $7,956,000 after purchasing an additional 5,332 shares during the period. Swiss National Bank raised its position in Sarepta Therapeutics by 6.3% during the first quarter. Swiss National Bank now owns 166,183 shares of the biotechnology company’s stock worth $21,514,000 after acquiring an additional 9,900 shares during the period. Finally, Oppenheimer Asset Management Inc. raised its position in Sarepta Therapeutics by 32.0% during the first quarter. Oppenheimer Asset Management Inc. now owns 3,604 shares of the biotechnology company’s stock worth $467,000 after acquiring an additional 874 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.